Recent Data in Relapsed/Refractory Acute Myeloid Leukemia

Opinion
Video

A medical oncologist reviews clinical trial data for revumenib and ziftomenib for patients with relapsed/refractory acute myeloid leukemia.

This is a video synopsis/summary of an OncView® featuring Ghayas C. Issa, MD.

Issa discusses emerging menin inhibitor data. Revumenib is an oral small molecule menin-KMT2A inhibitor taken twice daily. By disrupting the menin-KMT2A interaction it decreases leukemogenic gene expression, induces differentiation and demonstrates antileukemic effects. Early phase 1 first-in-human data showed a 60% response rate in heavily pretreated patients with 30% achieving complete remission/complete response. Confirmatory phase 2 data has since met the primary efficacy end point. Based on an approximately 25% complete response rate, FDA submission is planned. Adverse effects are mostly tolerable, including QTc prolongation (10%, grade 3+) and differentiation syndrome (15%, managed with steroids).

Ziftomenib is another menin inhibitor being studied, dosed once daily. Single-agent activity looked more promising for NPM1 mutant versus KMT2A-rearranged AML. Recently presented phase 1 data yielded 35% complete remission or complete remission with partial hematologic recovery in NPM1 cases, leading to differentiation syndrome sometimes requiring steroids. Otherwise the agents have minimal toxicities compared to chemotherapy. The main adverse effects are differentiation syndrome and QTc prolongation.

All trial efficacy data represents real-world outcomes, even being potentially lifesaving for some patients previously referred to hospice.

Video synopsis is AI-generated and reviewed by Cancer Network® editorial staff.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
Related Content
What Path to Approval Has Dasatinib Taken in CML/ALL?

What Path to Approval Has Dasatinib Taken in CML/ALL?

Ariana Pelosci
October 27th 2025
Article

Over the past 4 years, the FDA has accepted a number of NDA submissions for dasatinib, but it has yet to receive approval in CML/ALL.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

The FDA has set a Prescription Drug User Fee Act date of June 18, 2026, for approving this formulation of nilotinib in chronic myeloid leukemia.

FDA Accepts NDA for New Nilotinib Formulation in CML

Russ Conroy
October 23rd 2025
Article

The FDA has set a Prescription Drug User Fee Act date of June 18, 2026, for approving this formulation of nilotinib in chronic myeloid leukemia.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

A 13-week Good Laboratory Practice toxicity study demonstrated that UB-VV111 was well-tolerated in CD34-humanized mice.

FDA Grants Fast Track Designation to UB-VV111 in Select B-Cell Malignancies

Tim Cortese
October 1st 2025
Article

A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.

An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.

Indirect Comparison Favors Zanubrutinib vs Venetoclax Combo in CLL/SLL

Russ Conroy
September 26th 2025
Article

An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.